Total amount raised
$4.5 Billion
Latest funding date
1/1/2025
Location
Moderna has successfully raised funding over 17 rounds, with the latest being a Grant round. The company is backed by 25 investors, including the Coalition for Epidemic Preparedness Innovations and Ares Management.
Keep reading to explore the intricacies of Moderna's fundraising journey and the investors backing this innovative biotechnology company.
What Is Moderna?
Moderna, a biotechnology company based in Cambridge, Massachusetts, specializes in vaccines and drug development. Founded approximately in 2013, the company has grown significantly, employing between 1001 and 5000 people.
Moderna is renowned for its pioneering work in mRNA technology, aiming to create medicines that can treat or prevent diseases. The company is publicly traded under the ticker NASDAQ:MRNA and has made several notable investments and acquisitions in the biotechnology and pharmaceutical sectors.
How Much Funding Has Moderna Raised?
- Grant
- Amount Raised: USD 8,000,000
- Date: September 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: Likely aimed at supporting vaccine and drug development initiatives.
- Series G
- Amount Raised: USD 500,000,000
- Date: February 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of mRNA technology and expand the company's pipeline.
- Series H
- Amount Raised: USD 125,000,000
- Date: May 2018
- Lead Investors: Merck
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop mRNA-based vaccines and therapeutics.
- Grant
- Amount Raised: USD 483,000,000
- Date: April 2020
- Lead Investors: Biomedical Advanced Research and Development Authority (BARDA)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the development of a COVID-19 vaccine.
- Grant
- Amount Raised: USD 472,000,000
- Date: July 2020
- Lead Investors: Biomedical Advanced Research and Development Authority (BARDA)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further support COVID-19 vaccine development.
- Post-IPO Equity
- Amount Raised: USD 250,000,000
- Date: October 2022
- Lead Investors: DFO Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the company's vaccine portfolio and support ongoing research.
- Post-IPO Equity
- Amount Raised: USD 750,000,000
- Date: March 2024
- Lead Investors: Blackstone Life Sciences
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund the development of flu vaccines and diversify the vaccine portfolio.
- Grant
- Amount Raised: USD 176,000,000
- Date: July 2024
- Lead Investors: U.S. Department of Health & Human Services
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support public health initiatives and vaccine development.
- Post-IPO Debt
- Amount Raised: USD 600,000,000
- Date: November 2025
- Lead Investors: Ares Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To manage financial stability and support ongoing projects.
- Grant
- Amount Raised: USD 54,300,000
- Date: December 2025
- Lead Investors: Coalition for Epidemic Preparedness Innovations
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance epidemic preparedness and vaccine development.
Total Amount Raised: USD 3,414,300,000. Current Valuation: Not publicly disclosed.
Key Investors
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Details: CEPI is a global partnership launched to develop vaccines to stop future epidemics. It was founded in 2017 and is headquartered in Oslo, Norway.
- Investment Focus Areas: Vaccine development, epidemic preparedness, infectious diseases.
- Notable Investments: Moderna, Inovio Pharmaceuticals, CureVac.
- Ares Management
- Details: Ares Management is a global alternative investment manager offering investment services in credit, private equity, and real estate. Founded in 1997, it is headquartered in Los Angeles, California.
- Investment Focus Areas: Credit, private equity, real estate.
- Notable Investments: Neiman Marcus, Guitar Center, McGraw-Hill Education.
- U.S. Department of Health & Human Services (HHS)
- Details: HHS is a cabinet-level department of the U.S. federal government tasked with protecting the health of all Americans and providing essential human services. It was established in 1953.
- Investment Focus Areas: Public health, medical research, social services.
- Notable Investments: National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA).
- Blackstone Life Sciences
- Details: Blackstone Life Sciences is a division of Blackstone, a global investment firm. It focuses on investments in the life sciences sector, including biotechnology, pharmaceuticals, and medical technology companies.
- Investment Focus Areas: Biotechnology, pharmaceuticals, medical technology.
- Notable Investments: Moderna, Alnylam Pharmaceuticals, Reata Pharmaceuticals.
- Biomedical Advanced Research and Development Authority (BARDA)
- Details: BARDA is an office of the U.S. Department of Health & Human Services. It supports the development and procurement of medical countermeasures to protect against bioterrorism, pandemics, and other public health emergencies.
- Investment Focus Areas: Biodefense, pandemic preparedness, medical countermeasures.
- Notable Investments: Moderna, Johnson & Johnson, AstraZeneca.
What's Next for Moderna?
Moderna's future looks promising with a significant $750 million investment from Blackstone Life Sciences. This funding will enable the company to advance its research in mRNA technology and develop new vaccines, including those for flu, cancer, and RSV. The flu vaccine market alone is estimated at $7 billion, presenting a substantial growth opportunity.
With the new capital, Moderna can diversify its revenue streams and reduce risks associated with individual vaccine programs. The company is also considering using project financing models for other experimental vaccines, which could attract further investments. However, challenges such as high R&D expenses and declining COVID-19 vaccine sales remain. Overcoming these hurdles will be crucial for Moderna's continued success.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Moderna and gather other critical business insights.
Sign up for free to start making data-driven decisions and stay ahead of the competition.
